

HH

HEMP FOR HEALTH

Made in Tuscany
CSE: HFH | FSE: 9HH



DISCLAIMER

General: This presentation ("Presentation") has been compiled by Hemp for Health Inc. ("Hemp for Health") solely for information purposes. The presentation is not, and under no circumstances is to be construed to be, an offering of securities. Neither this presentation, nor its delivery to the recipient shall constitute an offer to sell, or the solicitation of an offer to buy the assets described herein. It is provided solely for use by prospective investors in considering their interest. No sales of the securities of Hemp for Health shall be made until Hemp for Health and the potential investor enter into a subscription agreement for such securities. The information contained herein has been prepared to assist interested parties in making their own evaluation of Hemp for Health and its business and does not purport to contain all the information that prospective investors may require. Prospective investors should conduct their own investigation and analysis of Hemp for Health and its business and the information contained in this presentation as well as any additional information provided by Hemp for Health. The information contained in this presentation is not to be used for any other purpose. Certain statutory rights for Canadian investors and key business and industry risk factors are included near the end of the presentation. **Market Data and Industry Data:** Market data and industry forecasts used in this Presentation were obtained from government or other industry publications, various publicly available sources or based on estimates derived from such publications and reports and management's knowledge of, and experience in, the markets in which Hemp for Health operates. Government and industry publications and reports generally indicate that they have obtained their information from sources believed to be reliable, but do not guarantee the accuracy and completeness of their information. Actual outcomes may vary materially from those forecast in such reports or publications, and the prospect for material variation can be expected to increase as the length of the forecast period increases. Although Hemp for Health believes that these sources are generally reliable, the accuracy and completeness of such information are not guaranteed and have not been independently verified. Further, market and industry data is subject to variations and cannot be verified due to limits on the availability and reliability of data inputs, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. **United States Matters:** The securities described herein have not been or will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws. Any securities offered will be offered only to qualified investors under exemptions from such registration requirements by subscription agreement. This Presentation does not constitute an offer of securities, and no offer or sale of securities will be conducted in any jurisdiction where such offer or sale is prohibited. **Cautionary Note to European Investors:** European laws, regulations and their enforcement, particularly those pertaining to anti-money laundering, relating to making and/or holding investments in cannabis- related practices or activities are in flux and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws – some of which carry criminal liability - and their effect on shareholders are uncertain and involve considerable risk. Accordingly, all potential investors located in Europe (including without limitation, the United Kingdom) should obtain their own, independent legal advice based on their own circumstances prior to making any investment in Hemp for Health (whether directly or indirectly, or acting on an agency or principal basis). **Cautionary Note Regarding Forward Looking Statements:** This presentation includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the approval of CBD by the US Food and Drug Administration will lead to validation of CBD therapeutic efficacy, the projected value of the CBD market worldwide over the next two years, the expected production capacity of Hemp for Health's facilities, and Hemp for Health's anticipated rollout of operations and sales. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" occur. Forward-looking statements are based on certain material assumptions and analysis made by Hemp for Health and the opinions and estimates of management as of the date of this presentation, including that approval of CBD by the US Food and Drug Administration will lead to validation of CBD therapeutic efficacy, the projected value of the CBD market worldwide will be as anticipated by Cannabis Newswire, the expected production capacity of Hemp for Health's facilities will be as anticipated by management, management's assessment of the anticipated production cost over the next three years for Hemp for Health's facility is accurate, management's assessment of Hemp for Health's anticipated revenue over the next three years is accurate and will be unaffected by any changes in the CBD market and Hemp for Health's anticipated rollout of operations will be as anticipated by management. Although Hemp for Health considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that approval of CBD by the US Food and Drug Administration will not lead to validation of CBD therapeutic efficacy, but rather will result in evidence that CBD does not have therapeutic efficacy, the projected value of the CBD market worldwide will not be as anticipated by Cannabis Newswire, or other listed sources, the expected production capacity of Hemp for Health's facilities will not be as anticipated by management, management's assessment of the anticipated production cost over the next three years for Hemp for Health's facility is not accurate, management's assessment of Hemp for Health's anticipated revenue over the next three years is not accurate and Hemp for Health's anticipated rollout of operations will not be as anticipated by management. Although management of Hemp for Health has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking statements or forward- looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Hemp for Health does not undertake to update any forward-looking statement, forward-looking information or financial outlook that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.





Made in Tuscany



OUR MISSION

Hemp for Health is positioned to become the only vertically integrated CBD company in Italy with a “Made in Tuscany” product, focused on bringing wellness to individuals across the European Union and beyond.

MANAGEMENT AND BOARD OF DIRECTORS

Robert EADIE, CEO

Mr. Eadie has been the catalyst behind several start up companies both public and private. Through his participation of over 20 years in the Capital Markets, he has raised over \$100 million because of his focus on open and transparent communication style and public relations expertise.

Gary ARCA, CFO, CPA

Mr. Arca is an international accounting professional with experience in start ups and company development. He is a Chartered Professional Account and has been a member of the Canadian Institute of Chartered Professional Accountants and British Columbia Institute of Chartered Professional Accountants since 1980.

Emiliano VANNI

Emiliano has been in sales and marketing of precious metals for 20 years and lives in Arezzo, Italy in Tuscany. He is responsible for sales, corporate development, marketing, pricing, and revenue management. He is an excellent communicator and has built good relationships around the local community and businesses.

Gina PALA

Currently a principal at AlliedOne Consulting since 2018 and Interim CIO at the Financial Institutions Commission since 2019. Prior thereto, Senior Vice President, Information Technology at BC Investment Management Corporation from 2010 to 2017.

SPECIAL ADVISORY

Marialuisa VESSICHELLI, AG

Ms Vessichelli is an Agronomist and the president of the Farmers Grow-Up in Italy. She specializes in micro irrigation and fertilization.

Cathy CARTER

Cathy Carter is President and CEO of Carter –Culp and Associates which develops and markets consumer goods products to mass merchants and e-commerce platforms internationally.






WHY CBD

The CBD market is touted to be a \$22 billion dollar industry and is revolutionizing the opioid crisis and prescription medicine industry.

Hemp for Health will target the wellness market with a “made in Tuscany” brand and CBD that is grown in the most sought-after soil in the world.



THE PLANT



CBD OIL



In 2019 the FDA recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significant interest in these possibilities.*



Cannabidiol (CBD) is a natural chemical compound found inside the Cannabis plant.



When CBD is carefully extracted & taken orally with other cannabinoids & terpenes of the plant, its benefits are increased & amplified. This is known as the "Entourage Effect."




Crude oil can be processed into a full-spectrum oil, distillate, or isolate (the most refined).

*<https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd>



CBD OIL IMPACT


- Reduces Seizures
- Non-Addictive
- Anti-Bacterial
- Promotes Better Sleep
- Reduces Risk of Artery Blockage
- Reduces Blood Sugar Levels
- Reduces Intestinal Contractions
- Vasorelaxant
- Relieves Pain



- Relieves Anxiety
- Promotes Healthy Immune Function
- Reduces Withdrawal Symptoms
- Suppresses Muscle Spasms
- Inhibits Cancer-cell Growth
- Reduces Nausea
- Non-Psychoactive
- Reduces inflammation
- Promotes Healthy Skin



OTHER BENEFITS



SKIN

CBD can treat psoriasis as it reduces the growth of the skin cells. CBD has an anti-inflammatory effect on sebaceous glands



HIGH BLOOD PRESSURE

CBD can reduce resting systolic blood pressure and stroke



RECOVERING ALCOHOLICS

CBD could be used as potential treatment for alcoholic liver diseases



PTSD

CBD may reduce the fear response in sufferers



MEDICINAL CBD – EPILEPSY IN CHILDREN



CBD can help treat severe and rare cases of child epilepsy. i.e. Charlotte Figi and her 300 seizures per week reduced to practically zero.

Cost efficient alternative - any prescription drugs are expensive and hard on low income families

**NEW ENGLAND JOURNAL OF MEDICINE
Cited 23% reduction in seizures in children taking CBD.**

ON THE MEDIA

Forbes

**"The European
CBD market is
expected to hit
\$417mm by end
of 2019 and \$1.7
billion by 2023"**

Forbes MAGAZINE
*American business
magazine*



**"The hemp-CBD
market
specifically has
projected growth
of 700%"**

Rolling Stone MAGAZINE
American monthly magazine

**"Europe's CBD
Market is
Estimated to
Grow 400%
Through 2023"**

Brightfield GROUP
*Predictive Consumer and Market
Intelligence
For the CBD & Cannabis
Industries*



OUR OPERATIONS

01

CULTIVATION

Contracts with tobacco farmers signed for test crop and future exclusive rights to farming hemp using existing land, dryers, and staff.



02 EXTRACTION/MANUFACTURER

Current test products being sold/delivered under three brands: Tuscan Gold, Bronze, Silver.

Following all EU GMP practices to ensure compliance with any future rulings.


03

DISTRIBUTION

A focus on e-commerce to sell to retail consumers as well as our current negotiations with various pharmacies in the EU and abroad.




TIMELINE




HEMP CBD MARKET

Category Analysis



EUROPEAN CBD MARKET FORECAST



European population is 740 Million

Predictions differ in a nascent market, but all assume growth

European market expected to see 400% growth through 2026



*Brightfield Group, Canaccord Research Paper, Statista

WHY US



COMPETITION

There is very little professional competition in the CBD market at the present time in Italy because there is a shortage of validated quality supply.

EXCLUSIVITY

The Company has direct access to farmers and processing capacity and is at the forefront of one of the fastest growing commodity markets that will increase exponentially over the next decade.

PRODUCTION

Based on a yield of 350 grams of flower per plant and 2000 plants per hectare, plus the use of bio-mass, trim and stems for downstream industrial products, the revenue and profitability in the current sellers' market on a pro forma basis, is expected to produce exponential returns.

GROWTH

By 2022 at full scale production from 1,500 hectares, the expected revenues of approx. €150 million will produce EBITDA in excess of approx. €120 million per year on a capital investment of €10million.

REVENUE STREAMS



HEMP FLOWER

The current market for hemp flower depending on quality and CBD concentration is between €100 per kilogram for poor quality (typically Chinese import) to €8,000 per kilogram for high quality above 20% CBD concentration. Our model is based on a mid grade flower at €600 per kilogram.



CBD OIL

CBD Crude oil of 45%+ purity can range from €2,500 - €3,500 per kilogram. Hemp for Health will use its own proprietary CBD extraction and distillation equipment and expects to sell its CBD in crude form in high volumes. Our model is based on bulk sales starting at €2,200 per kilogram.



WHITE LABEL

The Company expects to achieve a minimum of €1,800 per kilogram for sale volumes of over 10,000 kilograms.





EXTRACTION

**Supercritical Co2
is the preferred
extraction
method.**

**Non-toxic and non-
flammable making it
clean and safe**

**Control temperature
to manage quality
and extract most
cannabinoids and
terpenes**


**Make products that
resemble the plants
genetic structure and
get the "Entourage
Effect"**



SHAREHOLDER STRUCTURE

SHARE OWNERSHIP (as of March 2020)

- **Management and Directors**
- **Retail Brokers and Investors**



Shares Issued and Outstanding	25,162,001
Warrants (\$0.30)	10,009,800
Fully Diluted	37,171,801



CONTACT US

 [@HempForHealth1](https://www.facebook.com/HempForHealth1)

 [/hemp-for-health/](https://www.linkedin.com/company/hemp-for-health/)

 [@HempForHealth](https://twitter.com/HempForHealth)

 [@HempForHealth](https://www.instagram.com/HempForHealth)



580 Hornby St. Suite 750



+1 (604) 602-4935



info@hempforhealth.eu



www.hempforhealth.eu

